Jiuyou Capital
VC Fund
Jiuyou Capital is a VC fund focused on Biotechnology and Health Care. Jiuyou Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks and brokerages. Relying on the shared economy model of “Internet + Social + Finance”, Jiuyou Capital is committed to building a more optimized and efficient investment industryecosystem, and thus becomes China's most influential financial resource integration and service platform.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Jiuyou Capital invests in
Stages Jiuyou Capital invests in
Countries Jiuyou Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $854k–$43M
- Series B
- $2.8M–$80M
- Series C
- $2.9M–$145M
Investment Focus
Industry
- Biotechnology 9 (50%)
- Health Care 5 (28%)
- Pharmaceutical 5 (28%)
- Medical 4 (22%)
- Biopharma 3 (17%)
Stage
- Series A 5 (28%)
- Series B 5 (28%)
- Series C 3 (17%)
- Angel 2 (11%)
- Funding Round 2 (11%)
Country
- China 11 (61%)
- United States 2 (11%)
- Taiwan 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sun Yi
Managing partner
|
Managing partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jingxin Microelectronics
|
Jingxin Microelectronics is a developer of communication and information security chips including NRS1800, SDI3210, ESW5610, PRB0400 PCIe to SRIO and other chips and boards, enabling an efficient supply of high-speed data switching chips for the industry market. | $13.8M / Series B / May 20, 2024 | |
ReLive Biotechnologies LTD
|
ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science. | $43M / Series A / Jan 16, 2023 | |
| Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine.Maijing Gene was established in 2015 and is based in Guangzhou,China. | Series C / Dec 29, 2022 | ||
| Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development. | Series B / Nov 15, 2021 | ||
| OakMega is an AI company helping businesses grow by building trusted customer relationships with real-time 1st-party data. | Series A / May 10, 2021 | ||
| Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | Dec 31, 2020 | ||
| Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases. | $15M / Series A / Dec 01, 2020 | ||
| Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $144.7M / Series C / Aug 25, 2020 | ||
| SmartNuclide is a biopharmaceutical company that develops biological drug products. | $2.8M / Series B / Apr 23, 2020 | ||
| Linpowave offers a comprehensive range of millimeter-wave radar sensor systems for automobiles, drones, robots, and security applications. Their flagship single-chip 4D High-Resolution Radar and other advanced products support use cases such as drone obstacle avoidance, ground-following flight, robot SLAM, intelligent driving, and trafficmonitoring. With products already deployed in batches across these sectors, Linpowave ensures high-performance detection in all conditions. Regular updates and strong customer support enable seamless integration and long-term reliability in intelligent systems. | $7.1M / Nov 27, 2019 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Jiuyou Capital invest in?
Jiuyou Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jiuyou Capital's check size?
Jiuyou Capital typically joins rounds of $854k–$43M at Series A, $2.8M–$80M at Series B and $2.9M–$145M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jiuyou Capital participates in.
How do I contact Jiuyou Capital?
Public channels for Jiuyou Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Jiuyou Capital?
The team at Jiuyou Capital includes Sun Yi (Managing partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
